BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Biolex Therapeutics 

158 Credle Street

Pittsboro  North Carolina  27312  U.S.A.
Phone: 919-542-9901 Fax: 919-542-9910


SEARCH JOBS


Industry
Biotechnology






 Company News
Biolex Therapeutics Execs Gone Before Filing for $38 Million Bankruptcy 7/9/2012 8:06:30 AM    More...
Biolex Therapeutics Sells LEX System to Synthon and Initiates Sale of Locteron(R) 5/7/2012 8:47:49 AM    More...
OctoPlus' Licensee Biolex Therapeutics Presents Phase IIb Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated With Locteron 3/31/2011 9:02:41 AM    More...
OctoPlus' Licensee Biolex Therapeutics to Present Final Results of Locteron Phase IIb Study at EASL Conference 3/10/2011 9:55:20 AM    More...
Biolex Therapeutics to Present Final Phase 2b Results at EASL for Locteron(R) Next-Generation Controlled-Release Interferon for HCV 3/10/2011 9:52:37 AM    More...
Biolex Therapeutics Names Kurt Graves Executive Chairman as Company Prepares for Phase 3 Trials and Commercialization of Locteron(R) in Hepatitis C 11/9/2010 9:29:46 AM    More...
OctoPlus' Licensee Biolex Therapeutics Presents Significant Tolerability Advantages of Locteron at AASLD Conference Today 11/1/2010 9:46:22 AM    More...
Biolex Therapeutics Presents at AASLD Meeting Significant Tolerability Advantages of Locteron(R), Its Next-Generation Interferon for Hepatitis C 11/1/2010 9:30:04 AM    More...
Biolex Therapeutics Announces Locteron(R) SVR12 Results and Safety/Tolerability Advantages in SELECT-2 Hepatitis C Trial 10/28/2010 6:40:43 AM    More...
Biolex Therapeutics and Merial Broaden Collaboration 7/15/2010 12:44:28 PM    More...
1234

//-->